■胰腺癌的特征在于高侵袭性和暗淡的预后;优化相关的治疗决定取决于可靠的预后标志物的可用性。这项研究旨在比较各种血液生物标志物,如中性粒细胞/淋巴细胞比率(NLR),淋巴细胞/单核细胞比率(LMR),血小板/淋巴细胞比率(PLR),C反应蛋白(CRP),白蛋白(Alb),血浆纤维蛋白原(PF),和CRP/Alb在胰腺癌患者中的表达。
■我们的研究回顾性分析了2007年7月至2018年12月诊断为胰腺癌的250例患者。CutoffFinder应用程序用于计算CRP/Alb和PF的最佳值。采用卡方检验或Fisher精确检验分析CRP/Alb和PF与其他临床病理因素的相关性。进行单变量和多变量分析可以对这些预后因素进行进一步的生存分析。
■多变量分析表明,在232例胰腺导管腺癌(PDAC)患者中,PF水平对总生存期有统计学意义(风险比(HR)=0.464;p=0.023);然而,在整个250例胰腺癌患者组中未发现这种相关性.相反,CRP/Alb比值在整个胰腺癌队列(HR=0.471;p=0.026)和PDAC亚组(HR=0.484;p=0.034)中均有统计学意义.CRP/Alb与PF呈正相关(r=0.489,p<0.001),Spearman等级相关分析显示。此外,在232名PDAC患者中,与单独的CRP/Alb比值或PF浓度相比,CRP/Alb比值和PF的组合对预后具有协同作用.
■PF浓度是一个方便的,快速,和非侵入性生物标志物,结合CRP/Alb比值可显著提高胰腺癌患者预后预测的准确性,尤其是那些最常见的PDAC组织学亚型。
UNASSIGNED: Pancreatic carcinoma is characterised by high aggressiveness and a bleak prognosis; optimising related treatment decisions depends on the availability of reliable prognostic markers. This study was designed to compare various blood biomarkers, such as neutrophil/lymphocyte ratio (NLR), lymphocyte/monocyte ratio (LMR), platelet/lymphocyte ratio (PLR), C-reactive protein (CRP), albumin (Alb), plasma fibrinogen (PF), and CRP/Alb in patients with pancreatic carcinoma.
UNASSIGNED: Our study retrospectively reviewed 250 patients with pancreatic carcinoma diagnosed between July 2007 and December 2018. The Cutoff Finder application was used to calculate the optimal values of CRP/Alb and PF. The Chi-square test or Fisher\'s exact test was used to analyse the correlation of CRP/Alb and PF with other clinicopathological factors. Conducting univariate and multivariate analyses allowed further survival analysis of these prognostic factors.
UNASSIGNED: Multivariate analysis revealed that, in a cohort of 232 patients with pancreatic ductal adenocarcinoma (PDAC), the PF level exhibited statistical significance for overall survival (hazard ratio (HR) = 0.464; p = 0.023); however, this correlation was not found in the entire group of 250 patients with pancreatic carcinoma. Contrastingly, the CRP/Alb ratio was demonstrated statistical significance in both the entire pancreatic carcinoma cohort (HR = 0.471; p = 0.026) and the PDAC subgroup (HR = 0.484; p = 0.034). CRP/Alb and PF demonstrated a positive association (r=0.489, p<0.001) as indicated by Spearman\'s rank correlation analysis. Additionally, in 232 PDAC patients, the combination of the CRP/Alb ratio and PF had synergistic effects on prognosis when compared with either the CRP/Alb ratio or the PF concentration alone.
UNASSIGNED: PF concentration is a convenient, rapid, and noninvasive biomarker, and its combination with the CRP/Alb ratio could significantly enhance the accuracy of prognosis prediction in pancreatic carcinoma patients, especially those with the most common histological subtype of PDAC.